# Freezer Supplement to Hepatobiology and Toxicology COBRE

> **NIH NIH P20** · UNIVERSITY OF LOUISVILLE · 2022 · $68,000

## Abstract

The University of Louisville (UofL) Hepatobiology and Toxicology (H&T) COBRE is a unique thematic
center focused on liver research. The UofL H&T COBRE concentrates on the mechanisms and therapeutic
strategies for multiple forms of liver disease/injury, including: Non-alcoholic fatty liver disease/non-alcoholic
steatohepatitis—the most common liver disease in the US/worldwide, and is highly linked to the metabolic
syndrome; Alcoholic Liver Disease—a common problem among those who drink; Environmental Toxicant
Induced Liver Injury—an increasingly recognized problem, and Louisville has been a leader in this area;
Hepatitis B and C—important causes of cirrhosis and hepatocellular carcinoma worldwide; Personalized
Medicine—an increasingly important factor in medication efficacy, and most drugs are metabolized in the liver;
and Drug-Induced Liver Injury—the most common reason drugs are removed from the market and an
important cause of liver failure. This COBRE brings together experienced senior mentors/investigators and
promising junior investigators to perform cross-cutting research on the unique topics of Hepatobiology and
Toxicology. We address critical barriers in our understanding of the development/ progression of liver disease
and we define targets for prevention/treatment that could transform clinical practice.
 Specific Aims of the Hepatobiology and Toxicology COBRE are to:
1. Expand and strengthen a thematically-focused program in Hepatobiology and Toxicology that helps build
and sustain the overall research infrastructure at UofL.
2. Expand and strengthen the multidisciplinary program in research education, mentoring and career
development in Hepatobiology and Toxicology, and systematically track and evaluate the progress.
3. Provide the necessary research resources and translational science/basic technologies to support state-of-
the-art research in Hepatobiology and Toxicology and to ensure sustainability of the program.
4. Discover new mechanisms/molecular targets and effective means for preventing and/or treating liver
diseases/toxicant exposures and communicate our findings to the public.
 In summary, Phase I strengthened UofL’s biomedical research infrastructure through the establishment of
a thematic multidisciplinary center in hepatobiology and toxicology to enhance the ability of investigators to
compete for independent funding. In Phase I, we met or exceeded our metrics, including 1) four of our
investigators transitioning to independent research funding; 2) 91 mentee and 162 total publications; 3) new
renovated laboratory space; 4) numerous presentations; 5) establishing new collaborations; and 6) >$75
million in total new grant funding by H&T members. This Phase II proposal builds on our Phase I success,
extends and strengthens the scope of the program, and provides a roadmap for sustainability.

## Key facts

- **NIH application ID:** 10582198
- **Project number:** 3P20GM113226-07S1
- **Recipient organization:** UNIVERSITY OF LOUISVILLE
- **Principal Investigator:** CRAIG J. MCCLAIN
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $68,000
- **Award type:** 3
- **Project period:** 2016-06-10 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10582198

## Citation

> US National Institutes of Health, RePORTER application 10582198, Freezer Supplement to Hepatobiology and Toxicology COBRE (3P20GM113226-07S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10582198. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*